Paulmurugan et al. recently published a report where they delivered the FASN (fatty acid synthase) inhibitor orlistat to TNBC (triple-negative breast cancer) via folate-decorated polymeric nanoparticles leading to enhanced cytotoxicity [36]. Here, FASN is linked to triple-negative breast carcinoma.